Plain-English translation of NCT06786026 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy medication called paired with chemotherapy (a drug called nab-paclitaxel) to treat advanced or recurrent triple-negative breast cancer. Some participants will also receive , a drug that blocks blood vessel growth to tumors. Researchers want to see if this combination is effective and safe for women who have not yet received treatment for their advanced disease.
Triple-negative breast cancer is particularly aggressive because it lacks three common protein targets that make other breast cancers easier to treat. This medication represents a new approach using the immune system to fight this difficult-to-treat cancer type.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication combined with nab-paclitaxel chemotherapy, and possibly , depending on which treatment arm you are assigned to. You will attend multiple clinic visits for infusions and blood work to monitor how well the treatment is working and how your body tolerates it. The study will measure your tumor response using imaging scans and assess any side effects you experience throughout your treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~60 participants
Started
October 2024
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wang Hongxia
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.